Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Xu, Na  [Clear All Filters]
2024
Wu D, Tao S, Zhu L, Zhao C, Xu N. Chitosan Hydrogel Dressing Loaded with Adipose Mesenchymal Stem Cell-Derived Exosomes Promotes Skin Full-Thickness Wound Repair. ACS Appl Bio Mater. 2024.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.
Li R-X, Xu N, Guo Y-N, Wang Y, Liang Y-W, Zhou X-L, Jiang W-T, Wei J-X, Zhang X-Y, Zhou L-N, et al. Hemoglobin is associated with BMDs and risk of the 10-year probability of fractures in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2024;15:1305713.
Wang Y, Liu Q-F, Wu D-P, Xu Z-L, Han T-T, Sun Y-Q, Huang F, Fan Z-P, Xu N, Chen F, et al. Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. BMC Med. 2024;22(1):176.
2023
Zhang C, Zeng Y, Xu N, Zhang Z. [Cell-loaded hydrogel microspheres based on droplet microfluidics: a review]. Sheng Wu Gong Cheng Xue Bao. 2023;39(1):74-85.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Yang S, Zhang X, Gale RPeter, Du X, Chen C-Y, Weng J-Y, Huang J, Li F, Zeng Y, Xiao Z, et al. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, Xu Y, Xu N, Luo Y, Deng L, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8(1):348.
Wang Z, Fan Z, Wu Z, Xuan L, Li X, Tang B, Liu Y, He J, Huang K, Zhou X, et al. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023.
Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, Chi P, Xu Y, Xu N, Deng L, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023.
Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.
2022
Huang F, Zeng X, Fan Z, Xu N, Yu S, Xuan L, Liu H, Jin H, Lin R, Shi P, et al. Haplo-peripheral blood stem cell plus cord blood grafts for hematologic malignancies might lead to lower relapse compared with haplo-peripheral blood stem cell plus bone marrow grafts. Transplant Cell Ther. 2022.
2021
Dou X, Zheng F, Zhang L, Jin J, Zhang Y, Liu B, Meng L, Zhu X, Lu Z, Jia Y, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol. 2021.
2020
He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020;129:110390.
Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020.
2019
Yan Y, Wei Y, Yang R, Xia L, Zhao C, Gao B, Zhang X, Fu J, Wang Q, Xu N. Enhanced osteogenic differentiation of bone mesenchymal stem cells on magnesium-incorporated titania nanotube arrays. Colloids Surf B Biointerfaces. 2019;179:309-316.
2016
Jiang X, Xu L, Zhang Y, Huang F, Liu D, Sun J, Song C, Liang X, Fan Z, Zhou H, et al. Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 2016;5(5):e1139274.